Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety Study of GSK Biologicals' Hib-MenC+Infanrix Penta Vaccines and NeisVac-C (Meningitis C Vaccine;Baxter)+GSK's Infanrix Hexa vs. Meningitec (Men. C Vaccine;Wyeth)+Infanrix Hexa in Healthy Infants (2,4,6 M)

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Hib-MenC+Infanrix Penta Vaccines and NeisVac-C (Meningitis C Vaccine;Baxter)+GSK's Infanrix Hexa vs. Meningitec (Men. C Vaccine;Wyeth)+Infanrix Hexa in Healthy Infants (2,4,6 M)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP-hepatitis B-poliovirus vaccine; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 09 Sep 2011 Actual completion date is September 2010 according to ClinicalTrials.gov (extension trial: NCT00322335).
    • 09 Sep 2011 Actual start date is May 2006 according to ClinicalTrials.gov (extension trial: NCT00322335).
    • 21 Dec 2006 New trial record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top